Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this post-marketing surveillance study is to collect and assess information on
safety and efficacy of fondaparinux injection in patients with venous thromboembolism (VTE).
("Arixtra" is a trademark of the GlaxoSmithKline group of companies.)